Drug Profile
Metamfetamine - Sinapis Pharma
Alternative Names: Intravenous methamphetamine; IV methamphetamineLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator The University of Montana
- Developer Sinapis Pharma
- Class Amphetamines; Anorectics; Neuroprotectants; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Apoptosis inhibitors; Central nervous system stimulants; Cytokine stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Brain injuries; Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Brain injuries in USA (IV)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (IV)
- 11 Jul 2011 Sinapis Pharma completes a phase I trial in Brain injuries and stroke in USA